Literature DB >> 21883665

Malaria vaccines and the new malaria agenda.

B M Greenwood1, G A T Targett.   

Abstract

The development of an effective malaria vaccine has taken many decades, but there is now a good chance that the first malaria vaccine will be licensed within the next few years. However, this vaccine (RTS,S) will not be fully effective, and more efficacious, second-generation vaccines will be needed. Good progress is being made in the development of potential vaccines directed at each of the three main stages of the parasite's life cycle, with a variety of different approaches, but many challenges remain, e.g. overcoming the problem of polymorphism in many key parasite antigens. It is likely vaccines that are effective enough to block transmission, and thus contribute to increasing drives towards malaria elimination, will need to contain antigens from different stages of the parasite's life cycle.
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21883665     DOI: 10.1111/j.1469-0691.2011.03612.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  20 in total

1.  Expression, immunogenicity, histopathology, and potency of a mosquito-based malaria transmission-blocking recombinant vaccine.

Authors:  D K Mathias; J L Plieskatt; J S Armistead; J M Bethony; K B Abdul-Majid; A McMillan; E Angov; M J Aryee; B Zhan; P Gillespie; B Keegan; A R Jariwala; W Rezende; M E Bottazzi; D G Scorpio; P J Hotez; R R Dinglasan
Journal:  Infect Immun       Date:  2012-02-06       Impact factor: 3.441

2.  Operational Assessment of Long-Lasting Insecticidal Nets by Using an Anopheles Salivary Biomarker of Human-Vector Contact.

Authors:  Mahoutin H Noukpo; Georgia B Damien; Emmanuel Elanga-N'Dille; André B Sagna; Papa M Drame; Evelyne Chaffa; Olayidé Boussari; Vincent Corbel; Martin Akogbéto; Franck Remoue
Journal:  Am J Trop Med Hyg       Date:  2016-10-24       Impact factor: 2.345

3.  Toward a human vaccines project.

Authors:  Wayne C Koff; Ian D Gust; Stanley A Plotkin
Journal:  Nat Immunol       Date:  2014-07       Impact factor: 25.606

4.  RALP1 is a rhoptry neck erythrocyte-binding protein of Plasmodium falciparum merozoites and a potential blood-stage vaccine candidate antigen.

Authors:  Daisuke Ito; Tomoyuki Hasegawa; Kazutoyo Miura; Tsutomu Yamasaki; Thangavelu U Arumugam; Amporn Thongkukiatkul; Satoru Takeo; Eizo Takashima; Jetsumon Sattabongkot; Eun-Taek Han; Carole A Long; Motomi Torii; Takafumi Tsuboi
Journal:  Infect Immun       Date:  2013-09-03       Impact factor: 3.441

5.  Antimalarial activity of the myxobacterial macrolide chlorotonil a.

Authors:  Jana Held; Tamirat Gebru; Markus Kalesse; Rolf Jansen; Klaus Gerth; Rolf Müller; Benjamin Mordmüller
Journal:  Antimicrob Agents Chemother       Date:  2014-08-11       Impact factor: 5.191

6.  The evolutionary consequences of blood-stage vaccination on the rodent malaria Plasmodium chabaudi.

Authors:  Victoria C Barclay; Derek Sim; Brian H K Chan; Lucas A Nell; Maia A Rabaa; Andrew S Bell; Robin F Anders; Andrew F Read
Journal:  PLoS Biol       Date:  2012-07-31       Impact factor: 8.029

7.  Algae-produced Pfs25 elicits antibodies that inhibit malaria transmission.

Authors:  James A Gregory; Fengwu Li; Lauren M Tomosada; Chesa J Cox; Aaron B Topol; Joseph M Vinetz; Stephen Mayfield
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240

8.  Assessment of Anopheles salivary antigens as individual exposure biomarkers to species-specific malaria vector bites.

Authors:  Zakia M I Ali; Mahfoud Bakli; Albin Fontaine; Nawal Bakkali; Vinh Vu Hai; Stephane Audebert; Yvan Boublik; Frederic Pagès; Franck Remoué; Christophe Rogier; Christophe Fraisier; Lionel Almeras
Journal:  Malar J       Date:  2012-12-31       Impact factor: 2.979

9.  Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36.

Authors:  Nirianne Marie Q Palacpac; Edward Ntege; Adoke Yeka; Betty Balikagala; Nahoko Suzuki; Hiroki Shirai; Masanori Yagi; Kazuya Ito; Wakaba Fukushima; Yoshio Hirota; Christopher Nsereko; Takuya Okada; Bernard N Kanoi; Kohhei Tetsutani; Nobuko Arisue; Sawako Itagaki; Takahiro Tougan; Ken J Ishii; Shigeharu Ueda; Thomas G Egwang; Toshihiro Horii
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

Review 10.  Overview of plant-made vaccine antigens against malaria.

Authors:  Marina Clemente; Mariana G Corigliano
Journal:  J Biomed Biotechnol       Date:  2012-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.